1206675-01-5

Usage

Uses

Used in Pharmaceutical Industry:
(2-hydroxyphenyl)methanaminium acetate is used as a pH regulator and buffering agent for maintaining the stability and efficacy of pharmaceutical products. Its ability to control pH levels ensures that the active ingredients in medications remain effective and safe for consumption.
Used in Cosmetic Industry:
In the cosmetic industry, (2-hydroxyphenyl)methanaminium acetate serves as a pH regulator and buffering agent, helping to maintain the optimal pH levels in skincare and beauty products. This ensures that the products are gentle on the skin and effective in delivering their intended benefits.
Used in Organic Synthesis:
(2-hydroxyphenyl)methanaminium acetate has potential applications in the field of organic synthesis, where it can be utilized as a reagent or intermediate in the synthesis of various organic compounds. Its unique chemical properties make it a valuable component in creating new and innovative molecules.
Used in Chemical Research:
As a chemical compound with intriguing properties, (2-hydroxyphenyl)methanaminium acetate is of interest for further study in chemical research. Scientists and researchers can explore its potential applications, reactions, and interactions with other compounds to expand the understanding of its capabilities and uses.
Used in Medicine and Pharmacology:
Due to its potential biological activity, (2-hydroxyphenyl)methanaminium acetate may have applications in medicine and pharmacology. Further research and study could reveal its potential as a therapeutic agent or as a component in the development of new drugs and treatments.

Upstream product

• 94-67-7 salicylaldehyde-oxime 
• 64-19-7 acetic acid 
• 932-30-9 2-Hydroxybenzylamine 
• 90-02-8 salicylaldehyde 
• 390427-07-3 tert-butyl (2-hydroxybenzyl)carbamate 

Downstream Products

• 61626-91-3 o-hydroxyphenylmethylamine hydrochloride 
• 763071-62-1 N-[(2-phenol)methylene]-2-pyridinemethanamine 
• 1619935-41-9 (2-hydroxybenzyl)bis(2-hydroxy-3,5-di-tert-butylbenzyl)amine 
• 3946-40-5 N-(2-hydroxybenzyl)salicylaldimine 
• 932-30-9 2-Hydroxybenzylamine 

Relevant academic research and scientific papers

Synthesis and characterisation of aluminium(III) imine bis(phenolate) complexes with application for the polymerisation of rac-LA

A series of tridentate imine bis(phenolate) ligands have been synthesised and complexed to aluminium. Solid-state analysis identified two structural motifs of an aluminium dimer [Al2(Me)2(X)2]; one consisting of two five-c

Preparation method of salicylamine acetate

The invention discloses a preparation method of salicylamine acetate. The method comprises the following steps: (1) performing amino protection on salicylaldehyde with a structure shown in formula 1 to obtain a compound with a structure shown in formula 2

Preparation method of salicylamine acetate

The invention discloses a preparation method of salicylamine acetate. The method comprises the following steps: (1) protecting the amino groups of salicylaldehyde having a structure represented by formula 1 to obtain a compound having a structure represented by formula 2; and (2) carrying out acid hydrolysis on the compound of the formula 2, and then reacting the acid-hydrolyzed compound with acetic acid to obtain the salicylamine acetate.

Characterization of scavengers of γ-ketoaldehydes that do not inhibit prostaglandin biosynthesis

Expression of cyclooxygenase-2 (COX-2) is associated with the development of many pathologic conditions. The product of COX-2, prostaglandin H2 (PGH2), can spontaneously rearrange to form reactive γ-ketoaldehydes called levuglandins (LGs). This γ-ketoaldehyde structure confers a high degree of reactivity on the LGs, which rapidly form covalent adducts with primary amines of protein residues. Formation of LG adducts of proteins has been demonstrated in pathologic conditions (e.g., increased levels in the hippocampus in Alzheimer's disease) and during physiologic function (platelet activation). On the basis of knowledge that lipid modification of proteins is known to cause their translocation and to alter their function, we hypothesize that modification of proteins by LG could have functional consequences. Testing this hypothesis requires an experimental approach that discriminates between the effects of protein modification by LG and the effects of cyclooxygenase-derived prostanoids acting through their G-protein coupled receptors. To achieve this goal, we have synthesized and evaluated a series of scavengers that react with LG with a potency more than 2 orders of magnitude greater than that with the ε-amine of lysine. A subset of these scavengers are shown to block the formation of LG adducts of proteins in cells without inhibiting the catalytic activity of the cyclooxygenases. Ten of these selective scavengers did not produce cytotoxicity. These results demonstrate that small molecules can scavenge LGs in cells without interfering with the formation of prostaglandins. They also provide a working hypothesis for the development of pharmacologic agents that could be used in experimental animals in vivo to assess the pathophysiological contribution of levuglandins in diseases associated with cyclooxygenase up-regulation.